Press Release FeedGet the RSS feed
Menu

GlobeNewswire

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

GlobeNewswire

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026  and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.

  1. CryptoNew Crypto: AlphaPepe Presale Announces $3.1M as Ethereum Price Prediction Targets $10,000New crypto AlphaPepe has pushed beyond $3.1 million raised as the presale continues building momentum before its first public exchange chart. More than 12,600 holders are already onboard, with 100+ new buyers joining daily while $ALPE remains available at $0.03402.
  2. China Controls 99% of Gallium. Mount Ridley Mines (ASX: MRD) May Have Found the West's SolutionMount Ridley Mines (ASX: MRD) Selectro™ Process recovers 95% of gallium from bauxite, vs ~70% in Bayer refining, as China controls 99% of supply.
  3. FinanceDisc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockDisc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Disc from this offering are expected to be $450 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 22, 2026, subject to the satisfaction of customary closing conditions.
  4. FinanceWolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. InvestorsWolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
  5. FinanceROSEN, LEADING INVESTOR COUNSEL, Encourages Endava plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – DAVAWHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Endava plc (NYSE: DAVA) between September 4, 2025 and September 21, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2026.
  6. Webull Corporation Class Action Lawsuit Seeks Recovery for Investors; December 7 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLPDid you buy BULL securities between April 26, 2025 and October 6, 2026?